Global Renal Anemia Therapeutics Market Size By Type (DS-1093, EPO-018B), By Application (Hospital, Research Center), By Region, And Segment Forecasts, 2023 to 2032

The Global Renal Anemia Therapeutics Market was valued at USD 4.6 billion in 2023 and is projected to reach USD 7.9 billion by 2031, growing at a CAGR of 6.8% during the forecast period from 2023 to 2031. The market is being driven by the increasing prevalence of chronic kidney disease (CKD), the growing geriatric population, and advancements in erythropoiesis-stimulating agents (ESAs) and iron-based therapeutics. Renal anemia is a common complication of CKD, and early therapeutic intervention is crucial to improving patient quality of life and reducing the risk of cardiovascular complications.

Drivers:

Rising Prevalence of Chronic Kidney Disease (CKD):

With the global increase in conditions such as diabetes and hypertension, CKD cases are escalating, leading to a surge in renal anemia diagnoses. This drives the demand for effective therapeutics.

Advancements in Erythropoiesis-Stimulating Agents (ESAs):

Innovative and longer-acting ESAs are enhancing the treatment regimen and patient compliance. This has significantly impacted the therapeutic landscape of renal anemia.

Aging Population and Increased Dialysis Procedures:

The geriatric population is more susceptible to renal anemia, especially those undergoing hemodialysis. The rising number of dialysis centers worldwide further supports market growth.

Restraints:

Risk of Adverse Effects from ESA Therapy:

Long-term use of ESAs has been associated with adverse cardiovascular outcomes, including thrombosis and hypertension, potentially limiting their widespread use.

High Treatment Costs and Reimbursement Challenges:

Despite medical advances, the high cost of renal anemia therapies—especially in underfunded healthcare systems—poses affordability and accessibility issues for patients.

Opportunity:

Emergence of HIF-PH Inhibitors:

The development of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors introduces an oral alternative to injectable ESAs, offering new treatment pathways and market expansion possibilities.

Untapped Potential in Emerging Markets:

Countries in Latin America, Asia-Pacific, and the Middle East present lucrative opportunities due to improving healthcare infrastructure and rising awareness of CKD management.

Market by System Type Insights:

Based on system type, the ESA Therapy segment accounted for the largest share in 2023. The dominance is attributed to their proven efficacy and established use in anemia management for dialysis and non-dialysis CKD patients. However, HIF-PH Inhibitors are expected to witness the fastest growth due to their oral administration convenience and promising safety profiles.

Market by End-use Insights:

The Dialysis Centers segment held the largest share in 2023. Dialysis patients are among the most frequently treated for renal anemia, necessitating constant therapeutic intervention. Meanwhile, Hospitals are expected to grow steadily as they serve as primary centers for anemia diagnosis and ESA initiation.

Market by Regional Insights:

North America dominated the global renal anemia therapeutics market in 2023, thanks to its robust healthcare infrastructure, high awareness levels, and the presence of major pharmaceutical players. However, the Asia-Pacific region is poised for the fastest growth due to an expanding CKD population, increasing healthcare investments, and the entry of cost-effective therapies.

Competitive Scenario:

Key players in the Global Renal Anemia Therapeutics Market include Amgen Inc., Roche Holding AG, Vifor Pharma, Akebia Therapeutics, Astellas Pharma Inc., FibroGen Inc., GlaxoSmithKline plc, Pfizer Inc., Janssen Pharmaceuticals, and Kyowa Kirin Co., Ltd. These companies are investing in product innovation, regulatory approvals, and strategic partnerships to strengthen their foothold in the market.

Scope of Work – Global Renal Anemia Therapeutics Market

Report Metric Details

Market Size (2023) USD 4.6 billion

Projected Market Size (2031) USD 7.9 billion

CAGR (2023–2031) 6.8%

Market Segments By System Type (ESA Therapy, HIF-PH Inhibitors), By End-use (Dialysis Centers, Hospitals)

Growth Drivers Rising CKD prevalence, ESA advancements, aging population

Opportunities HIF-PH innovation, growth in emerging healthcare markets

Key Market Developments:

2023: Akebia Therapeutics received regulatory approval for its HIF-PH inhibitor in select Asia-Pacific markets, expanding access to oral therapies for renal anemia.

2024: Amgen launched a new formulation of darbepoetin alfa with improved shelf stability, reducing cold-chain logistics dependency.

2025: Roche Holding AG initiated Phase III trials of a next-gen biosimilar ESA, targeting cost-sensitive markets across Latin America and Eastern Europe.

FAQs:

1) What is the current market size of the Global Renal Anemia Therapeutics Market?

The market was valued at USD 4.6 billion in 2023.

2) What is the major growth driver of the Global Renal Anemia Therapeutics Market?

The major growth driver is the rising prevalence of chronic kidney disease (CKD) globally.

3) Which is the largest region during the forecast period in the Global Renal Anemia Therapeutics Market?

North America holds the largest regional share, driven by advanced healthcare infrastructure and early adoption of novel therapies.

4) Which segment accounted for the largest market share in Global Renal Anemia Therapeutics Market?

ESA Therapy was the leading segment by system type in 2023.

5) Who are the key market players in the Global Renal Anemia Therapeutics Market?

Key players include Amgen Inc., Roche Holding AG, Vifor Pharma, Akebia Therapeutics, and Astellas Pharma Inc.